SYRE
Spyre Therapeutics, Inc. - Common Stock (SYRE)
$04
About Spyre Therapeutics, Inc. - Common Stock (SYRE)
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Details
Daily high
$100.00
Daily low
$92.77
Price at open
--
52 Week High
$110.18
52 Week Low
$21.14
Market cap
9.2B
Dividend yield
-
Volume
24
Avg. volume
1.2M
P/E ratio
-45.54
Spyre Therapeutics, Inc. - Common Stock News
Details
Daily high
$100.00
Daily low
$92.77
Price at open
--
52 Week High
$110.18
52 Week Low
$21.14
Market cap
9.2B
Dividend yield
-
Volume
24
Avg. volume
1.2M
P/E ratio
-45.54